机译:致命转移性前列腺癌的进化史
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK,Department of Human Genetics, KU Leuven, Herestraat 49 Box 602, B-3000 Leuven, Belgium,Cancer Research UK London Research Institute, London WC2A 3LY, UK;
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
Norwich Medical School and Department of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK,The Genome Analysis Centre, Norwich NR4 7UH, UK;
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA;
Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Maryland 20892, USA,Avoneaux Medical Institute, Oxford, Maryland 21654, USA;
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;
University of Liverpool and HCA Pathology Laboratories, London WC1E 6JA, UK;
Division of Genetics and Epidemiology, The Institute Of Cancer Research, London SW7 3RP, UK;
Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK;
Uro-oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK;
Uro-oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK,Department of Surgical Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK;
Norwich Medical School and Department of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK,Division of Genetics and Epidemiology, The Institute Of Cancer Research, London SW7 3RP, UK;
Division of Genetics and Epidemiology, The Institute Of Cancer Research, London SW7 3RP, UK,Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK Sutton SM2 5PT, UK;
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;
Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;
机译:基因表达小组预测诊断为临床局限性前列腺癌的男性的转移致死性前列腺癌结局
机译:早期,致命转移性前列腺癌的多学科干预:2015年科菲-霍尔登前列腺癌学院会议的报告
机译:基于完全家庭历史的前列腺癌死亡的相对风险
机译:鉴定前列腺癌患者血液中循环多能癌症干细胞诊断转移性癌症
机译:用于转移性前列腺癌休眠研究和抗癌疗法开发的3D球体培养系统。
机译:致命转移性前列腺癌的进化史
机译:致命转移性前列腺癌的进化史